Cat. No. 3439
Chemical Name: 1-Hexadecyl-2-methyl-3-(phenylmethyl)-1H-imidazolium iodide
Biological ActivityEukaryotic elongation factor 2 (eEF-2) kinase (CaMK III) inhibitor (IC50 = 60 nM) that displays 125-fold, > 1300-fold and > 1500-fold selectivity over PKC, PKA and CaMK II respectively. Decreases the viability of a variety of cancer cell lines (IC50 values are 0.7 - 4.8 μM) and blocks G1/S cell cycle progression. Shown to induce eEF-2 phosphorylation in cancer cells. Also an effective antibacterial agent; inhibits histidine protein kinase in vitro (IC50 = 6.6 μM) and in vivo.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Yamamoto et al (2001) Antibacterial agents that inhibit histidine protein kinase YycG of Bacillus subtilis. Biosci.Biotechnol.Biochem. 65 2306. PMID: 11758928.
Arora et al (2003) Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res. 63 6894. PMID: 14583488.
Arora et al (2004) P-glycoprotein mediates resistance to histidine kinase inhibitors. Mol.Pharmacol. 66 460. PMID: 15322237.
Chen (2011) 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J.Biol.Chem. 286 43951. PMID: 22020937.
If you know of a relevant citation for this product please let us know.
Keywords: NH 125, supplier, CaM, kinase, III, CAMK, eEF-2, inhibitors, Histidine, protein, kinases, Calmodulin-Activated, calmodulin-dependent, Protein, NH125
Find multiple products by catalog number
New Products in this Area
Potent MSK1 inhibitor; also inhibits other AGC group kinasesLH 846
Selective casein kinase 1δ inhibitorPPY A
Potent inhibitor of Abl T315l mutant and wild-type Abl kinasesFlavopiridol hydrochloride
Cyclin-dependent kinase inhibitorGSK2578215A
Potent, selective LRRK2 inhibitor; brain penetrantAmlexanox
Inhibitor of TBK1 and IKKε; antiallergic agentPF 05212384
Potent and selective dual PI 3-kinase/mTOR inhibitorPF 03814735
Aurora kinase A and B inhibitorPF 04691502
Dual PI 3-K/mTOR inhibitorTNP
Inhibitor of IP6K; also inhibits IP3KACHP
Selective IKKα and IKKβ inhibitorPD 0332991 isethionate
Potent, selective Cdk4/6 inhibitor; brain penetrantCZC 24832
Selective inhibitor of PI 3-Kinase γLY 333531 hydrochloride
Protein kinase C inhibitor; selective for β isozymesPF 06465469
Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK10Z-Hymenialdisine
Pan kinase inhibitor; potently inhibits MEK-1CP 690550 citrate
Potent JAK inhibitorWYE 687 dihydrochloride
Potent and selective mTOR inhibitor
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.